Brief: Tasly Pharma's 2021 Net Profit Up 109.5% Y/Y

NovaBridge Biosciences

30/03/2022 09:22

March 30 (Reuters) - Tasly Pharmaceutical Group Co Ltd
 600535.SS :
    * SAYS 2021 NET PROFIT UP 109.5% Y/Y
    * SAYS IT RECORDS 619 MILLION YUAN  ($97.43 million) LOSSES
FROM
INVESTMENT AT I-MAB  IMAB.O  BASED ON FAIR VALUE AS OF MARCH 30

Source text 1 http://static.sse.com.cn/disclosure/listedinfo/announcement/c/new/2022-03-31/600535_20220331_1_95elvTdQ.pdf
 
Source text 2 http://static.sse.com.cn/disclosure/listedinfo/announcement/c/new/2022-03-31/600535_20220331_22_95FZ8cjT.pdf
Further company coverage:  600535.SS 

($1 = 6.3530 Chinese yuan renminbi)

 (Reporting by Hong Kong newsroom)
 ((meg.shen@thomsonreuters.com; 852-39525805;))